Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Zevra Therapeutics OCF Yield % Related Terms
Zevra Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zevra Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (ZVRA) has a OCF Yield % of 4.98 as of Aug. 13, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Zevra Therapeutics and its competitors. According to the industry distribution chart, Zevra Therapeutics ranks #128 out of 1409 companies in the Biotechnology industry, placing it in the top 9.1%.
Is Zevra Therapeutics' OCF Yield % too high?
Zevra Therapeutics' current OCF Yield % is 4.98. Based on the distribution chart, Zevra Therapeutics ranks #128 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' OCF Yield % compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #128 out of 1409 companies for OCF Yield %. This places Zevra Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Zevra Therapeutics and its competitors. Zevra Therapeutics's current OCF Yield % is 4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $20.92, compared to a current price of $11.30 — trading 46% below its estimated fair value. The current OCF Yield % is 4.98. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current OCF Yield % is 4.98 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (ZVRA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of $11.30 is trading 46% below its estimated GF Value™ of $20.92.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for ZVRA:
OCF Yield %: 4.98
GF Value™: $20.92 vs. price of $11.30 (46% below fair value)
No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score
Get the complete analysis for ZVRA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZVRA has been successfully added to your 
